drugset / Trial / NCT03392467

PNEUMOSTEM for the Prevention and Treatment of Severe BPD in Premature Infants

NCT03392467 ↗

Phase 2 Completed 60 enrolled Medipost Co Ltd.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study is to evaluate the efficacy and safety of PNEUMOSTEM® for the Prevention and Treatment of Severe Bronchopulmonary Dysplasia (Severe BPD) in Premature Infants. Half of subjects will receive PNEUMOSTEM, while the other half will receive a placebo.

Timeline

Start
2018-08-13
Primary completion
2024-01-09
Completion
2024-10-18

Drugs

EvaluationDrugModalityDoseRoute
Subject PNEUMOSTEM® Cell therapy — —